Cholesterol drug takes aim at cancer protein in early trial
NCT ID NCT03560882
First seen May 07, 2026 · Last updated May 07, 2026 · Updated 1 time
Summary
This early-phase study tests whether atorvastatin, a widely used cholesterol medication, can reduce levels of a faulty protein called p53 in people with various cancers, including solid tumors and relapsed acute myeloid leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or treatment. The main goal is to measure changes in the mutant p53 protein, not to treat the cancer directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Cancer Center - CRC
Fairway, Kansas, 66205, United States
Conditions
Explore the condition pages connected to this study.